An allosteric transport mechanism for the AcrAB-TolC Multidrug Efflux Pump
- Baylor College of Medicine, United States
- The University of Texas Health Science Center at Houston Medical School, United States
- MRC Mitochondrial Biology Unit, United Kingdom
- University of Cambridge, United Kingdom
Abstract
Bacterial efflux pumps confer multidrug resistance by transporting diverse antibiotics from the cell. In Gram-negative bacteria, some of these pumps form multi-protein assemblies that span the cell envelope. Here we report the near-atomic resolution cryoEM structures of the Escherichia coli AcrAB-TolC multidrug efflux pump in resting and drug transport states, revealing a quaternary structural switch that allosterically couples and synchronizes initial ligand binding with channel opening. Within the transport-activated state, the channel remains open even though the pump cycles through three distinct conformations. Collectively, our data provide a dynamic mechanism for the assembly and operation of the AcrAB-TolC pump.
Data availability
-
Crystal structure of AcrBZ complex: 2017Publicly available at PDB (accession no: 5NC5).
-
The apo structure of AcrAB-TolC tripartite multidrug efflux pump: 2017Publicly available at EBI Protein Data Bank (accession no: EMD-8636).
-
The asymmetric structure of AcrAB-TolC tripartite multidrug efflux pump: 2017Publicly available at EBI Protein Data Bank (accession no: EMD-8640).
-
The symmetric structure of AcrAB-TolC tripartite multidrug efflux pump with inhibitor MBX3132 bound: 2017Publicly available at EBI Protein Data Bank (accession no: EMD-3636).
-
The apo structure of AcrAB-TolC tripartite multidrug efflux pump: 2017Publicly available at PDB (accession no: 5V5S).
-
The asymmetric structure of AcrAB-TolC tripartite multidrug efflux pump: 2017Publicly available at PDB (accession no: 5V78).
-
The symmetric structure of AcrAB-TolC tripartite multidrug efflux pump with inhibitor MBX3132 bound: 2017Publicly available at PDB (accession no: 5NG5).
Article and author information
Author details
Funding
Wellcome
- Ben F Luisi
Human Frontier Science Program
- Ben F Luisi
National Institutes of Health (P41GM103832)
- Wah Chiu
American Heart Association (16GRNT29720001)
- Irina I Serysheva
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2017, Wang et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 13,319
- views
-
- 1,962
- downloads
-
- 202
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
An allosteric transport mechanism for the AcrAB-TolC Multidrug Efflux Pump
eLife 6:e24905.
https://doi.org/10.7554/eLife.24905
Further reading
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
African trypanosomes are the causative agents of neglected tropical diseases affecting both humans and livestock. Disease control is highly challenging due to an increasing number of drug treatment failures. African trypanosomes are extracellular, blood-borne parasites that mainly rely on glycolysis for their energy metabolism within the mammalian host. Trypanosomal glycolytic enzymes are therefore of interest for the development of trypanocidal drugs. Here, we report the serendipitous discovery of a camelid single-domain antibody (sdAb aka Nanobody) that selectively inhibits the enzymatic activity of trypanosomatid (but not host) pyruvate kinases through an allosteric mechanism. By combining enzyme kinetics, biophysics, structural biology, and transgenic parasite survival assays, we provide a proof-of-principle that the sdAb-mediated enzyme inhibition negatively impacts parasite fitness and growth.
-
- Structural Biology and Molecular Biophysics
The relationship between protein dynamics and function is essential for understanding biological processes and developing effective therapeutics. Functional sites within proteins are critical for activities such as substrate binding, catalysis, and structural changes. Existing computational methods for the predictions of functional residues are trained on sequence, structural, and experimental data, but they do not explicitly model the influence of evolution on protein dynamics. This overlooked contribution is essential as it is known that evolution can fine-tune protein dynamics through compensatory mutations either to improve the proteins’ performance or diversify its function while maintaining the same structural scaffold. To model this critical contribution, we introduce DyNoPy, a computational method that combines residue coevolution analysis with molecular dynamics simulations, revealing hidden correlations between functional sites. DyNoPy constructs a graph model of residue–residue interactions, identifies communities of key residue groups, and annotates critical sites based on their roles. By leveraging the concept of coevolved dynamical couplings—residue pairs with critical dynamical interactions that have been preserved during evolution—DyNoPy offers a powerful method for predicting and analysing protein evolution and dynamics. We demonstrate the effectiveness of DyNoPy on SHV-1 and PDC-3, chromosomally encoded β-lactamases linked to antibiotic resistance, highlighting its potential to inform drug design and address pressing healthcare challenges.
